Adolor/GSK Arixtra Co-Promotion Deal Could Pave Way For Entereg Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Under the two-year deal, Adolor will hire 30 surgeon-focused sales reps to collaborate with GSK reps in co-promoting Arixtra. The collaborative sales force also could market Adolor/GSK's Entereg, which is under review at FDA for postoperative ileus.
You may also be interested in...
FDA Requests Entereg Failed Study Data, Adolor Says
Alvimopan failed to show statistical significance for the primary endpoint in partner GlaxoSmithKline’s Phase III study. The pending NDA for the postoperative ileus therapy is based on three studies with mixed results.
FDA Requests Entereg Failed Study Data, Adolor Says
Alvimopan failed to show statistical significance for the primary endpoint in partner GlaxoSmithKline’s Phase III study. The pending NDA for the postoperative ileus therapy is based on three studies with mixed results.
GSK/Adolor Entereg Gets Standard Review For Postoperative Ileus Despite Fast Track Status
NDA submission was completed June 25 under FDA's continuous marketing application Pilot 1 program. There are no approved POI treatments, firm says. Chronic constipation and opioid bowel dysfunction alvimopan filings are projected for 2007.